Vanguard Capital Management
LXRX icon

Vanguard Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vanguard Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8M Buy
9,901,208
+382,041
+4% +$744K ﹤0.01% 2351
2026
Q1 		$14.8M Buy
+9,519,167
New +$13.8M ﹤0.01% 2505

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management's LXRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Lexicon Pharmaceuticals (LXRX) stake by 4% in Q2 2026, buying an estimated $744K and bringing the position to 9,901,208 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

Vanguard Capital Management first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Vanguard Capital Management held 9,901,208 shares of Lexicon Pharmaceuticals worth $23.8M as of Q2 2026.
  • Vanguard Capital Management bought 382,041 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $744K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2351 holding.
  • Vanguard Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.